MX2025001020A - Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal - Google Patents

Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal

Info

Publication number
MX2025001020A
MX2025001020A MX2025001020A MX2025001020A MX2025001020A MX 2025001020 A MX2025001020 A MX 2025001020A MX 2025001020 A MX2025001020 A MX 2025001020A MX 2025001020 A MX2025001020 A MX 2025001020A MX 2025001020 A MX2025001020 A MX 2025001020A
Authority
MX
Mexico
Prior art keywords
preparation
fused ring
method therefor
ring compound
medicinal application
Prior art date
Application number
MX2025001020A
Other languages
English (en)
Inventor
Xin Li
Guodong Cai
Feng Shen
Feng He
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2025001020A publication Critical patent/MX2025001020A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a un compuesto de anillo fusionado, un método de preparación para el mismo y una aplicación medicinal del mismo. Específicamente, la presente invención se refiere a un compuesto de anillo fusionado representado por la fórmula general (IN), un método de preparación para el mismo, una composición farmacéutica que contiene el compuesto y un uso del mismo como agente terapéutico, en particular, el uso del mismo en la preparación de un fármaco para inhibir KRAS G12D. Cada grupo en la fórmula general (IN) es como se define en la descripción. (ver Fórmula).
MX2025001020A 2022-07-27 2025-01-24 Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal MX2025001020A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN202210891331 2022-07-27
CN202211467809 2022-11-22
CN202211724856 2022-12-27
CN202211724115 2022-12-30
CN202310120312 2023-02-15
CN202310234194 2023-03-10
CN202310676437 2023-06-08
PCT/CN2023/109598 WO2024022444A1 (zh) 2022-07-27 2023-07-27 稠环类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2025001020A true MX2025001020A (es) 2025-03-07

Family

ID=89705453

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025001020A MX2025001020A (es) 2022-07-27 2025-01-24 Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal

Country Status (8)

Country Link
EP (1) EP4563580A4 (es)
JP (1) JP2025524846A (es)
KR (1) KR20250042155A (es)
CN (1) CN119365465A (es)
CA (1) CA3261072A1 (es)
MX (1) MX2025001020A (es)
TW (1) TW202409051A (es)
WO (1) WO2024022444A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CN119365467A (zh) 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
AU2023396551A1 (en) * 2022-12-15 2025-06-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyrimidine-containing polycyclic derivative inhibitor, and preparation method therefor and use thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
WO2024208305A1 (zh) * 2023-04-07 2024-10-10 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121843945A (zh) * 2023-07-18 2026-04-10 泰励生物科技(上海)有限公司 具有抗kras突变肿瘤活性的化合物
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
WO2025045141A1 (en) * 2023-08-31 2025-03-06 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025108443A2 (en) * 2023-11-23 2025-05-30 Beigene Switzerland Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
AU2025209726A1 (en) * 2024-01-17 2026-07-09 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
TW202535411A (zh) * 2024-01-24 2025-09-16 大陸商上海翰森生物醫藥科技有限公司 嘧啶多環類衍生物抑制劑、其製備方法和應用
WO2025157260A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物的可药用盐及其晶型
CN119490512B (zh) * 2024-01-26 2026-06-16 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119661555B (zh) * 2024-01-26 2026-04-14 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
WO2025157261A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物晶型及其制备方法
CN119684315B (zh) * 2024-01-26 2026-05-12 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025256655A1 (zh) * 2024-06-14 2025-12-18 上海翰森生物医药科技有限公司 一种含嘧啶多元并环类衍生物抑制剂的晶型及其制备方法
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026073024A1 (en) * 2024-09-30 2026-04-02 Gilead Sciences, Inc. Kras g12d inhibitors for the treatment of cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026098684A1 (zh) * 2024-11-11 2026-05-15 上海科州药物股份有限公司 作为kras抑制剂的杂环化合物,及其制备和治疗用途
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875242B1 (fr) 2004-09-10 2006-11-17 Biomerieux Sa Nouveaux substrats enzymatiques derives de phenoxazinone et leur utilisation comme revelateur dans la detection de microorganismes a activite peptidase
ES2924698T3 (es) 2015-05-28 2022-10-10 Theravance Biopharma R&D Ip Llc Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN112119075B (zh) 2018-08-16 2024-03-12 豪夫迈·罗氏有限公司 稠环化合物
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN113874374B (zh) 2019-05-24 2024-12-27 江苏恒瑞医药股份有限公司 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2021000885A1 (zh) 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
CN114615981B (zh) * 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CR20220258A (es) 2019-12-11 2022-07-03 Lilly Co Eli Inhibidores de kras g12c
GB202011996D0 (en) 2020-07-31 2020-09-16 Adorx Therapeutics Ltd Antagonist compounds
EP4204412A4 (en) 2020-08-26 2024-10-09 InventisBio Co., Ltd. HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF
WO2022148422A1 (en) 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
CN116867792A (zh) 2021-02-09 2023-10-10 基因泰克公司 四环氧氮杂䓬化合物及其用途
US20240199644A1 (en) * 2021-03-07 2024-06-20 Jacobio Pharmaceuticals Co., Ltd. Fused Ring Derivatives Useful as KRAS G12D Inhibitors
CN117043167A (zh) * 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022232331A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Heterocyclic compounds and methods of use
WO2022247757A1 (zh) 2021-05-26 2022-12-01 南京明德新药研发有限公司 氟取代的嘧啶并吡啶类化合物及其应用
MX2023015533A (es) * 2021-06-21 2024-01-23 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
CN115557974A (zh) 2021-07-02 2023-01-03 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
CN117677624A (zh) * 2021-07-19 2024-03-08 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
CA3226720A1 (en) * 2021-07-23 2023-01-26 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
WO2023025116A1 (zh) * 2021-08-25 2023-03-02 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
TW202315626A (zh) 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
EP4511127A1 (en) * 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN119365467A (zh) * 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途

Also Published As

Publication number Publication date
EP4563580A4 (en) 2025-10-29
JP2025524846A (ja) 2025-08-01
EP4563580A1 (en) 2025-06-04
CN119365465A (zh) 2025-01-24
CA3261072A1 (en) 2025-04-07
WO2024022444A1 (zh) 2024-02-01
TW202409051A (zh) 2024-03-01
KR20250042155A (ko) 2025-03-26

Similar Documents

Publication Publication Date Title
MX2023015533A (es) Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
MX2025001619A (es) Inhibidor de pde4b y uso del mismo
MX2025001700A (es) Compuestos triciclicos y uso medico de los mismos
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
MX2025000291A (es) Compuesto heterocíclico capaz de inhibir prmt5•mta y uso del mismo
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
CR20240160A (es) Compuestos espirocíclicos
MX2023006193A (es) Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina.
TW200503775A (en) Pharmaceutical composition and method for treating
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
ZA202501471B (en) Preparation and use of quinazolinone derivative as kinase inhibitor
ZA202400988B (en) Aak1 inhibitor and use thereof
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2026001837A (es) Compuestos que contienen ciclobutilo
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
MX2025013245A (es) Compuesto de camptotecina deuterado, preparacion y uso de este
MX2023005086A (es) Compuestos de pirimidina, composiciones y aplicaciones medicas de esta.
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
MX2023005078A (es) Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
CA3136727A1 (en) Methods of administering an arip-iprazole injectable preparation
MX2024000999A (es) Antagonista de molécula pequeña de lpa1.
MX2025005318A (es) Compuesto de cucurbiturilo y uso medico del mismo
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor